Management of Kaposi sarcoma after solid organ transplantation: A European retrospective study.
J Am Acad Dermatol
; 81(2): 448-455, 2019 Aug.
Article
en En
| MEDLINE
| ID: mdl-30902727
ABSTRACT
BACKGROUND:
Systemic therapeutic management of post-transplant Kaposi sarcoma (KS) is mainly based on 3 axes reduction of immunosuppression, conversion to mammalian target of rapamycin (mTOR) inhibitors, chemotherapy, or a combination of these.OBJECTIVE:
To obtain an overview of clinical strategies about the current treatment of KS.METHODS:
We conducted a multicenter retrospective cohort study including 145 solid organ transplant recipients diagnosed with KS between 1985 and 2011 to collect data regarding first-line treatment and response at 6 months.RESULTS:
Overall, 95%, 28%, and 16% of patients had reduction of immunosuppression, conversion to mTOR inhibitor, and chemotherapy, respectively. Patients treated with chemotherapy or mTOR inhibitor conversion were more likely to have visceral KS. At 6 months, 83% of patients had response, including 40% complete responses.LIMITATIONS:
The retrospective design of the study.CONCLUSION:
Currently available therapeutic options seem to be effective to control KS in most patients. Tapering down the immunosuppressive regimen remains the cornerstone of KS management.Palabras clave
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Sarcoma de Kaposi
/
Neoplasias Cutáneas
/
Protocolos de Quimioterapia Combinada Antineoplásica
/
Trasplante de Órganos
/
Inmunosupresores
/
Antineoplásicos
Tipo de estudio:
Etiology_studies
/
Observational_studies
/
Risk_factors_studies
Límite:
Adult
/
Female
/
Humans
/
Male
/
Middle aged
País/Región como asunto:
Europa
Idioma:
En
Año:
2019
Tipo del documento:
Article